公开(公告)号：WO2008118356A3

公开(公告)日：2008-11-20

申请号：PCT/US2008003735

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA ,  BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。

公开(公告)号：WO2008047134A3

公开(公告)日：2008-06-12

申请号：PCT/GB2007003983

申请日：2007-10-18

Applicant: UCB PHARMA SA ,  ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE ,  RAPECKI STEPHEN EDWARD

Inventor： ADAMS RALPH ,  POPPLEWELL ANDREW GEORGE ,  RAPECKI STEPHEN EDWARD

IPC: C07K16/24 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C12N15/13

CPC classification number: C07K16/468 ,  A61K39/3955 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：WO2006131322A3

公开(公告)日：2007-04-19

申请号：PCT/EP2006005405

申请日：2006-06-07

Applicant: UCB PHARMA SA ,  VERDRU PETER

Inventor： VERDRU PETER

IPC: A61K31/4015 ,  A61P25/08

CPC classification number: A61K31/4015

Abstract: The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies.

Abstract translation: 本发明涉及布立西坦用于制备有效预防或治疗进行性肌阵挛性癫痫的药物的用途。

公开(公告)号：WO2006128693A3

公开(公告)日：2007-04-19

申请号：PCT/EP2006005200

申请日：2006-05-31

Applicant: UCB PHARMA SA ,  KENDA BENOIT ,  QUESNEL YANNICK ,  ATES ALI ,  MICHEL PHILIPPE ,  TURET LAURENT ,  MERCIER JOEL

Inventor： KENDA BENOIT ,  QUESNEL YANNICK ,  ATES ALI ,  MICHEL PHILIPPE ,  TURET LAURENT ,  MERCIER JOEL

IPC: C07D401/06 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/435 ,  C07D403/06 ,  C07D473/00

CPC classification number: C07D513/04 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04

Abstract: The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract translation: 本发明涉及2-氧代-1-吡咯烷衍生物，其制备方法，含有它们的药物组合物及其作为药物的用途。

公开(公告)号：WO2013068563A3

公开(公告)日：2013-06-27

申请号：PCT/EP2012072325

申请日：2012-11-09

Applicant: UCB PHARMA SA

Inventor： ADAMS RALPH ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILLIP ,  HUMPHREYS DAVID PAUL

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/44 ,  C07K16/46

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及用于产生所述抗体分子的方法。

公开(公告)号：WO2012164397A8

公开(公告)日：2013-04-18

申请号：PCT/IB2012001231

申请日：2012-06-04

Applicant: UCB PHARMA SA ,  MCLOUGHLIN MARTIN J

Inventor： MCLOUGHLIN MARTIN J

IPC: A61M5/20 ,  A61M5/32

CPC classification number: A61M5/14546 ,  A61M5/1452 ,  A61M5/158 ,  A61M5/172 ,  A61M5/20 ,  A61M5/3129 ,  A61M5/3134 ,  A61M5/3137 ,  A61M5/31511 ,  A61M5/3202 ,  A61M5/3204 ,  A61M5/3213 ,  A61M5/326 ,  A61M5/5086 ,  A61M2005/206 ,  A61M2005/3139 ,  A61M2005/3152 ,  A61M2005/3215 ,  A61M2202/04 ,  A61M2205/27 ,  A61M2205/276 ,  A61M2205/33 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/584 ,  A61M2205/586 ,  A61M2205/8206 ,  F04C2270/0421

Abstract: There is provided a cassette unit that is suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe that is suitable for use in the injected delivery of drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby, acts such as to close off, the needle projection aperture. The cassette unit includes a cap lock feature movable from a first cap locking position in which it prevents removal of the removable cap from the capping position with the cassette unit to a second cap non-locking position in which it no longer prevents such cap removal.

Abstract translation: 提供了适用于具有电动驱动单元的自动注射器的盒单元。 盒单元具有限定盒单元容纳腔和针投影孔的壳体。 盒式单元容纳腔布置成接收适合用于将药物注射到患者体内的注射器。 盒单元包括可拆卸的盖，其在封盖位置中装配并且由此起作用以关闭针突出孔。 盒单元包括盖锁定功能，其可从第一盖锁定位置移动，其中防止将盒可拆卸盖从封盖位置移除到第二盖非锁定​​位置，在该第二盖非锁定​​位置，其不再阻止该盖移除。

公开(公告)号：WO2012178169A3

公开(公告)日：2013-04-11

申请号：PCT/US2012044017

申请日：2012-06-25

Applicant: UCB PHARMA SA ,  TORRIS ANTHONY ,  BRAMLEY ALISTAIR ,  FORMOSA DAN ,  FREITAG ERIC

Inventor： TORRIS ANTHONY ,  BRAMLEY ALISTAIR ,  FORMOSA DAN ,  FREITAG ERIC

IPC: A61M5/32 ,  A61M5/50

CPC classification number: A61M5/3232 ,  A61M5/3134 ,  A61M5/3137 ,  A61M5/31573 ,  A61M5/3204 ,  A61M5/321 ,  A61M5/326 ,  A61M5/34 ,  A61M5/5066 ,  A61M2005/3264 ,  A61M2005/3289 ,  A61M2207/00 ,  Y10T29/49826

Abstract: Systems, devices, and methods are provided for providing safe syringe assemblies for injections. The syringe assemblies include a shielding mechanism that covers a syringe needle after an injection is delivered, thereby reducing the risk of a subsequent accidental stab from the needle. The shielding mechanism has a pre-injection configuration in which the needle extends beyond the housing and a post-injection configuration in which at least one component of the syringe assembly covers the needle. In some implementations, the syringe assembly includes a lock that inhibits the assembly from returning to the pre-injection configuration once an injection is delivered. The syringe assemblies may also include a bevel orientation mechanism that allows a user to align a needle bevel to accurately insert a needle for injection.

Abstract translation: 提供了系统，装置和方法，用于为注射提供安全的注射器组件。 注射器组件包括在输注之后覆盖注射器针头的屏蔽机构，从而降低后续的针头意外刺伤的风险。 屏蔽机构具有预注射构造，其中针延伸超过壳体和后注射构造，其中注射器组件的至少一个部件覆盖针。 在一些实施方案中，注射器组件包括一旦一旦注射被输送就禁止组件返回到预注射构型的锁。 注射器组件还可以包括斜面定向机构，其允许使用者对准针斜面以精确地插入用于注射的针。

公开(公告)号：WO2012164403A3

公开(公告)日：2013-01-31

申请号：PCT/IB2012001426

申请日：2012-06-04

Applicant: UCB PHARMA SA ,  MCLOUGHLIN MARTIN J

Inventor： MCLOUGHLIN MARTIN J

IPC: A61M5/32 ,  A61M5/20

CPC classification number: A61M5/14546 ,  A61M5/1452 ,  A61M5/158 ,  A61M5/172 ,  A61M5/20 ,  A61M5/3129 ,  A61M5/3134 ,  A61M5/3137 ,  A61M5/31511 ,  A61M5/3202 ,  A61M5/3204 ,  A61M5/3213 ,  A61M5/326 ,  A61M5/5086 ,  A61M2005/206 ,  A61M2005/3139 ,  A61M2005/3152 ,  A61M2005/3215 ,  A61M2202/04 ,  A61M2205/27 ,  A61M2205/276 ,  A61M2205/33 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/584 ,  A61M2205/586 ,  A61M2205/8206 ,  F04C2270/0421

Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The cassette unit housing cavity is arranged for receipt of a syringe suitable for use in the injected delivery of drug to a patient. The cassette unit includes a needle cover defining a needle sheath. The removable cap is provided with a connector defining one or more needle cover gripping elements for gripping the needle cover. The connector defines a central hub and the one or more needle gripper elements attach to the central hub and in spaced arrangement relative to each other. The connector locates within the removable cap such that the central hub of the connector is in spaced relationship with a far end wall or surface of the cap interior.

Abstract translation: 提供了适用于具有电动驱动单元的自动注射器的盒单元。 盒单元具有限定盒单元容纳腔和针投影孔的壳体。 磁带盒单元容纳腔布置成接收适合用于将药物注射到患者体内的注射器。 盒单元包括限定针鞘的针盖。 可拆卸盖设置有限定用于夹持针罩的一个或多个针盖夹持元件的连接器。 连接器限定了中心毂，并且一个或多个针夹持件附接到中心毂并且相对于彼此间隔开排列。 连接器位于可移除盖内，使得连接器的中心毂与帽内部的远端壁或表面间隔开。

公开(公告)号：WO2012164394A3

公开(公告)日：2013-01-31

申请号：PCT/IB2012001172

申请日：2012-06-04

Applicant: UCB PHARMA SA ,  MCLOUGHLIN MARTIN J

Inventor： MCLOUGHLIN MARTIN J

IPC: A61M5/20 ,  A61M5/32

CPC classification number: A61M5/14546 ,  A61M5/1452 ,  A61M5/158 ,  A61M5/172 ,  A61M5/20 ,  A61M5/3129 ,  A61M5/3134 ,  A61M5/3137 ,  A61M5/31511 ,  A61M5/3202 ,  A61M5/3204 ,  A61M5/3213 ,  A61M5/326 ,  A61M5/5086 ,  A61M2005/206 ,  A61M2005/3139 ,  A61M2005/3152 ,  A61M2005/3215 ,  A61M2202/04 ,  A61M2205/27 ,  A61M2205/276 ,  A61M2205/33 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/584 ,  A61M2205/586 ,  A61M2205/8206 ,  F04C2270/0421

Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit has a housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity is arranged for receipt of a syringe for injected delivery of a drug to a patient. The cassette unit includes a removable cap that in a capping position fits over and thereby acts to close off the needle projection aperture; and connecting to the removable cap, a needle cover defining a needle sheath for sheathing the needle tip of the syringe. The removable cap is provided with one or more first engagement features arranged for selectively engaging one or more second engagement features of the cassette unit housing when the removable cap is in the capping position to thereby restrict/prevent rotation of the removable cap and needle cover relative to the housing.

Abstract translation: 提供了适用于具有电动驱动单元的自动注射器的盒单元。 盒单元具有限定盒单元容纳腔和针投影孔的壳体。 壳体空腔设置成接收用于将药物注射到患者体内的注射器。 盒单元包括可拆卸盖，其在封盖位置配合，从而用于封闭针突出孔; 并且连接到所述可移除盖，所述针盖限定用于护套所述注射器的针尖的针鞘。 可拆卸盖设置有一个或多个第一接合特征，其布置成当可拆卸盖处于封盖位置时选择性地接合盒单元壳体的一个或多个第二接合特征，从而限制/防止可移除盖和针盖相对的旋转 到房屋

公开(公告)号：WO2012022982A3

公开(公告)日：2012-06-21

申请号：PCT/GB2011051563

申请日：2011-08-19

Applicant: UCB PHARMA SA ,  HUMPHREYS DAVID PAUL ,  PETERS SHIRLEY JANE ,  ADAMS RALPH ,  HEADS JAMES

Inventor： HUMPHREYS DAVID PAUL ,  ADAMS RALPH ,  HEADS JAMES

IPC: C07K16/00 ,  A61K39/395

CPC classification number: C07K16/24 ,  A61K39/39591 ,  C07K16/00 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/94

Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.

Abstract translation: 本发明提供了包含至少一个包含CH1结构域和铰链区的重链的IgG4类抗体，其中在每条重链中：a。 在CH1结构域中根据Kabat编号系统编号的第127位的链间半胱氨酸被另一个氨基酸取代; 和b。 位于上铰链区的一个或多个氨基酸被半胱氨酸取代。